Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VTGN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVistagen appoints Angel Angelov as Chief Medical Officer with $425K salary and 150K options
Filed May 19, 2026 · Period ending May 18, 2026 · ~1 min read
Key Changes
-
medium
Dr. Angel Angelov, 57, joins as CMO effective May 18, 2026. He previously served as CMO at Theranica and held senior medical roles at Karuna Therapeutics and Neurocrine Biosciences, bringing deep experience in neurological and psychiatric drug development.
Item 5.02 verify on EDGAR → -
low
Compensation package includes $425,000 annual base salary, $50,000 signing bonus (paid in two installments), and eligibility for 45% annual bonus based on performance goals set by the Board.
Item 5.02 verify on EDGAR → -
low
Dr. Angelov received stock options for 150,000 shares at $0.5955 exercise price, vesting over four years (cliff after year one, then monthly over three years). Options expire in ten years.
Item 5.02 verify on EDGAR → -
low
Company entered standard indemnification agreement with Dr. Angelov to protect him from personal liability arising from his executive service, consistent with typical officer protections.
Exhibit 10.1 verify on EDGAR →
Summary
Vistagen Therapeutics appointed Dr. Angel Angelov as Chief Medical Officer, filling a critical leadership role for the clinical-stage biopharmaceutical company. Dr. Angelov brings 30+ years of experience in neurological and psychiatric drug development, having most recently served as CMO at Theranica and in senior medical affairs positions at Karuna Therapeutics and Neurocrine Biosciences.
His expertise aligns with Vistagen's focus on developing treatments for psychiatric and neurological conditions. The compensation package is structured to retain Dr. Angelov long-term: a competitive $425,000 base salary, performance-based bonus potential, and equity incentives that vest over four years.
The stock options, priced at $0.5955 per share (the May 18 closing price), represent about 0.1% dilution at current share counts and align his interests with shareholders through the four-year vesting schedule. Retail investors should monitor how Dr. Angelov's appointment impacts Vistagen's clinical trial execution and regulatory strategy. His track record at companies that have advanced CNS therapies through development could signal accelerated progress on Vistagen's pipeline. Watch for updates on clinical trial timelines and any strategic shifts in the company's development programs in upcoming quarterly calls.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Vistagen announced Dr. Angelov's appointment via press release furnished under Regulation FD.
Added in current filing · verify on EDGAR →
A copy of the press release announcing Dr. Angelov’s appointment is attached to this Current Report on Form 8-K as Exhibit 99.1.
Vistagen disclosed the appointment of Dr. Angelov through a press release furnished under Item 7.01 (Regulation FD Disclosure). The 8-K body does not specify the role or details of the appointment, which are contained in the attached press release exhibit. This is a standard Regulation FD disclosure mechanism for making material non-public information available to all investors simultaneously.
Event · Item 9.01 — Financial Statements and Exhibits
Vistagen entered an indemnification agreement with Angel S. Angelov, M.D., MBA and issued a press release on May 19, 2026.
Added in current filing · verify on EDGAR →
Indemnification Agreement by and between Vistagen Therapeutics, Inc. and Angel S. Angelov, M.D., MBA, dated May 18, 2026
Vistagen executed an indemnification agreement with Angel S. Angelov, M.D., MBA on May 18, 2026. Indemnification agreements typically protect directors or officers from personal liability arising from their service to the company. This suggests Dr. Angelov may be joining the board or taking an executive role, though the 8-K does not specify his position.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify